Teva (NYSE: TEVA) CFO converts 19,916 RSUs into ordinary shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries EVP and CFO Eliyahu Sharon Kalif acquired shares through vested equity awards. On March 5, 2026, he exercised 19,916 Restricted Share Units at $0.00 per unit, converting them into 19,916 Ordinary Shares.

Following the transactions, his reported direct holdings were 59,748 Restricted Share Units and 325,435 Ordinary Shares. The RSUs stem from a March 5, 2025 grant, with additional tranches of 19,916 units scheduled to vest on March 5 of 2027, 2028, and 2029.

Insider Trade Summary

19,916 shares exercised/converted

Mixed 2 txns

Insider Kalif Eliyahu Sharon

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	19,916	$0.00	--
Exercise	Ordinary Shares	19,916	$0.00	--

Holdings After Transaction: Restricted Share Units — 59,748 shares (Direct); Ordinary Shares — 325,435 shares (Direct)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on March 5, 2025, with 19,916 vested on March 5, 2026, and 19,916 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalif Eliyahu Sharon

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		19,916	A	(2)	325,435	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			19,916	(3)	(3)	Ordinary Shares(1)	19,916	$0	59,748	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on March 5, 2025, with 19,916 vested on March 5, 2026, and 19,916 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Teva (TEVA) report for its CFO?

Teva reported that EVP and CFO Eliyahu Sharon Kalif exercised 19,916 Restricted Share Units into 19,916 Ordinary Shares at $0.00 per share. This reflects scheduled vesting from a prior equity grant rather than an open-market stock purchase or sale.

How many Teva shares does the CFO hold after this Form 4 transaction?

After the exercise and conversion, Eliyahu Sharon Kalif reported 325,435 Ordinary Shares held directly and 59,748 Restricted Share Units. These positions reflect equity compensation awards and their vesting schedule, as disclosed in the Form 4 filing footnotes and transaction tables.

What are Restricted Share Units in the Teva CFO’s compensation?

Each Teva Restricted Share Unit represents a contingent right to receive one Ordinary Share or, at the committee’s option, the cash value of one Ordinary Share. They vest over time, aligning executive compensation with long-term company performance and continued service requirements.

When do the Teva CFO’s remaining Restricted Share Units vest?

Restricted Share Units were granted on March 5, 2025, with 19,916 vesting on March 5, 2026. Additional tranches of 19,916 RSUs are scheduled to vest on March 5 of 2027, 2028, and 2029, subject to the applicable award terms.

Does the Teva Form 4 show the CFO buying or selling shares on the market?

The Form 4 shows a derivative exercise and conversion of 19,916 Restricted Share Units into Ordinary Shares at $0.00 per share. It does not report an open-market stock purchase or sale, but rather settlement of previously granted equity awards.